TB006
Expanded Access Program
TB006 is an investigational medicine offering a potentially anti-inflammatory approach to treating Alzheimer's disease (AD) and a wide range of dementias.
This investigational drug targets Galectin-3 (Gal3), a protein with dual roles in the progression of these diseases:
-
Formation of harmful brain aggregates: Gal3 contributes to forming toxic oligomers and plaques, disrupting communication between neurons and leading to cognitive decline.
-
Regulation of inflammation: Gal3 over-activation triggers excessive microglial activity and chronic neuroinflammation, further damaging neurons.
By selectively blocking Gal3, TB006 potentially disrupts both of these pathways. It potentially prevents harmful brain aggregates while reducing neuroinflammation, potentially reversing some damage and restoring cognitive function. Early clinical trials show promising results for treating various dementias, including:
-
Vascular dementia
-
Frontotemporal dementia
-
Lewy body dementia
-
Dementia with mixed pathology
Beyond these specific types, TB006's unique mechanism of action suggests its potential to benefit individuals with other dementias as well. This opens up exciting possibilities for the future of dementia treatment.
TB006 offers hope for millions of individuals and their families. It represents a potentially significant breakthrough in the fight against dementia, paving the way for a brighter future and improved quality of life for those affected by this debilitating condition.